TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the third quarter of 2024 on Wednesday, November 6, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webca ...

Core Insights - Teva Pharmaceutical Industries Ltd. announced long-term improvement in Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over a three-year period in European patients [1][2] - The RIM-TD open-label extension study showed that 65% of patients achieved treatment success as defined by the Clinical Global Impression of Change (CGIC) and 56% by the Patient Global Impression of Change (PGIC) [2] - Deutetrabenazine is already approved in the United States and several other markets, addressing a significant unmet medical need in the treatment of TD [2][4] Industry Context - Tardive Dyskinesia affects approximately 15%-25% of patients on antipsychotic medications, leading to involuntary movements that significantly impair quality of life [2][3] - Current treatment options in Europe are limited and often lack robust clinical evidence, resulting in suboptimal management of the condition [2][3] - The positive outcomes from the RIM-TD study align with previous findings in the overall and U.S. populations, reinforcing the efficacy of deutetrabenazine as a treatment option for TD [2][3]

As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-'749 Currently, there is no long-acting olanzapine treatment option available for the treatment of schizophrenia that does not contain a boxed warning for Post-Injection Delirium/Sedation Syndrome (PDSS) New Phase 3 SOLARIS and Phase 1 safety data show no incidence of PDSS in study participants receiving TEV-'749 to date TEL AVIV, Israel & PARSIPP ...

Teva Pharmaceuticals Industries Limited (NYSE:TEVA) Bank of America Global Healthcare Conference September 18, 2024 3:15 AM ET Company Participants Richard Francis - President & CEO Conference Call Participants Jason Gerberry - BofA Securities Jason Gerberry Thank you, Richard, for joining us here at the BofA Global Healthcare Conference in London. My name is Jason Gerberry. I'm one of the SMID cap biotech and specialty pharma analysts. And so pleased to be introducing our next company presenter, Teva Pharm ...

Teva Pharmaceutical Industries Limited's (TEVA) stock has risen 72.5% so far this year compared with an increase of 17.9% for the industry. The stock has also outperformed the sector and the S&P 500, as seen in the chart below. TEVA Stock Outperforms Industry, Sector & S&P 500 Zacks Investment Research Image Source: The stock has also been consistently trading above 200-day moving averages since mid-November 2023. In fact, Teva's stock price is showing improvement after years of remaining suppressed. Teva i ...

JHVEPhoto Israel-based Teva Pharmaceutical Industries Limited (NYSE:TEVA), which develops both generic and branded drugs, looks poised to benefit from multiple, significant, positive catalysts over the medium term and long term. One of these drivers is the increasing demand for generic drugs due to a favorable macro and political environment for these products. Moreover, the demand for Teva's own generic and branded drugs is rising a great deal, and chances are high that the latter trends will continue goin ...

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) and Hewlett Packard Enterprise Co (NYSE:HPE) are this week's picks for Schaeffer's Cheap Seats: Stocks Under $20 segment. Both stocks are trading in the $18 region and sporting 2024 gains. Looking at Teva Pharmaceuticals stock first, the Israel-based pharma name is outperforming with a 78.9% yearto-date lead. The equity is hovering just below its Aug. 27 five-year high of $18.89, up 0.3% at $18.61 at last glance. Well above all notable short- and long-term dail ...

Jose Luis Pelaez Inc/DigitalVision via Getty Images As the AI hype bubble continues to deflate, fears about a potential US recession intensify, and risks of a large-scale war in the Middle East remain, Teva Pharmaceutical's stock price (NYSE:TEVA) is moving in an accumulation phase above $17, reflecting the continued strength of the bulls. What are the reasons for Wall Street's growing optimism about the Israeli company, which is one of the leaders in the generic drug market? First, on July 31, Teva release ...

Teva Pharmaceutical Industries (TEVA) reported second-quarter 2024 adjusted earnings of 61 cents per share, which beat the Zacks Consensus Estimate of 57 cents. Adjusted earnings rose 9% from 56 cents reported in the year-ago quarter. Revenues for the second quarter came in at $4.16 billion, which beat the Zacks Consensus Estimate of $3.99 billion. Total revenues rose 7% on a reported basis and 11% on a constant currency basis. Sales growth was mainly driven by higher revenues from generic products globally ...

Financial Data and Key Metrics Changes - Revenue increased to $4.2 billion, up 11% year-over-year [6][18] - Adjusted EBITDA rose to $1.2 billion, a 4% increase [6] - Non-GAAP EPS increased to $0.61, up 9% [6][21] - GAAP operating loss improved to $5 million from a loss of $654 million in the same quarter last year [18] - GAAP net loss was $846 million, compared to a net loss of $872 million in Q2 2023 [18] Business Line Data and Key Metrics Changes - Innovative business continued to grow rapidly, contributing significantly to overall revenue [6] - Generics business grew by 14%, with strong performance across all regions [6][11] - TAPI API segment grew by 5%, marking the second consecutive quarter of growth [6][11] Market Data and Key Metrics Changes - AUSTEDO revenue reached $407 million, reflecting a 32% growth [7] - AJOVY grew by 12%, driven primarily by European and international markets [7] - UZEDY showed strong momentum with a favorable product profile attracting new physicians [8] Company Strategy and Development Direction - The company is focused on a "pivot to growth" strategy with four pillars: delivering on growth engines, stepping up innovation, sustaining generics powerhouse, and focusing the business [4][5] - The strategy has resulted in six consecutive quarters of growth, with a strong emphasis on innovative products and generics [5][27] - The company plans to launch additional biosimilars, including a biosimilar of Stelara in February 2025 [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong performance from AUSTEDO, UZEDY, AJOVY, and the generics business [27] - The company is committed to achieving mid-single-digit revenue growth and a 30% operating margin by 2027 [27] - Management acknowledged the dynamic nature of the biosimilars market and the need for strategic positioning [48] Other Important Information - Free cash flow for Q2 2024 was $324 million, down from $632 million in Q2 2023 [23] - The company is reframing its 2024 free cash flow guidance to a range of $1.7 billion to $2 billion [23][25] - Net debt at the end of Q2 2024 was $16.4 billion, with gross debt decreasing to $18.6 billion [24] Q&A Session Summary Question: Can you talk about the composition of the API business? - Management highlighted that TAPI works across all technologies and platforms, making it the second-largest API manufacturer globally [29][30] Question: Do you expect to be on the CMS list for 2027 regarding AUSTEDO? - Management indicated that the $2.5 billion target for AUSTEDO in 2027 accounts for potential changes in the payer landscape [30] Question: What is working for AUSTEDO and where is there room for improvement? - Management credited a strong team and effective execution for AUSTEDO's momentum, with ongoing efforts to increase diagnosis and patient adherence [32][33] Question: Can you quantify the impact of SIMLANDI? - Management noted significant interest and coverage from payers for SIMLANDI, with expectations for market share growth in Q3 and Q4 [32][33] Question: Can you discuss operating leverage and long-term spending? - Management emphasized the importance of investing in growth while maintaining a focus on operational efficiency to achieve significant operating leverage [36][37] Question: How does M&A fit into the neuroscience business? - Management stated that while they are open to M&A, they are selective and focused on complementary assets that align with their growth strategy [38] Question: What is the outlook for generic Revlimid? - Management acknowledged the need to replace revenue from Revlimid post-2026 and is focusing on launching high-value complex generics [40][41] Question: What is the current state of the biosimilars market in the US? - Management observed a growing appetite among payers for biosimilars, indicating a shift in market dynamics [45][48]